Analyst Rating Update on ABIOMED (ABMD)

ABIOMED (NASDAQ:ABMD) : Zacks Investment Research ranks ABIOMED (NASDAQ:ABMD) as 3, which is a Hold recommendation. 5 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 1 other analysts are mildly bullish on the stock and favor a Buy. A total of 2 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 8 research analysts is 1.63, which indicates as a Buy.

ABIOMED (NASDAQ:ABMD) : 8 Wall Street analysts covering ABIOMED (NASDAQ:ABMD) believe that the average level the stock could reach for the short term is $110. The maximum price target given is $130 and the minimum target for short term is around $55, hence the standard deviation is calculated at $24.99.

For the current week, the company shares have a recommendation consensus of Buy.

ABIOMED (NASDAQ:ABMD): stock turned positive on Tuesday. Though the stock opened at $101.94, the bulls momentum made the stock top out at $105.35 level for the day. The stock recorded a low of $101.25 and closed the trading day at $105.09, in the green by 3.81%. The total traded volume for the day was 667,003. The stock had closed at $101.23 in the previous days trading.

In an insider trading activity, The Securities and Exchange Commission has divulged that Greenfield Andrew J, officer (VP Healthcare Solutions) of Abiomed Inc, had unloaded 9,000 shares at an average price of $104.16 in a transaction dated on June 7, 2016. The total value of the transaction was worth $937,440.

Abiomed, Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Companys products include Impella 2.5, a percutaneous micro heart pump with an integrated motor and sensors; Impella CP, which is primarily used by either interventional cardiologists to support patients in the catheter lab or by surgeons in the heart surgery suite; Impella 5.0 and Impella LD, a percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump that is designed to allow greater than four liters of flow per minute; AB5000, a circulatory support system for the temporary support of acute heart failure patients in profound shock, and Symphony, a minimally invasive implantable cardiac assist device.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.